127 related articles for article (PubMed ID: 11138278)
1. [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Urologe A; 2000 Nov; 39(6):554-6. PubMed ID: 11138278
[TBL] [Abstract][Full Text] [Related]
2. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
[TBL] [Abstract][Full Text] [Related]
3. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
Oremek GM; Teigelkamp S; Kramer W; Eigenbrodt E; Usadel KH
Anticancer Res; 1999; 19(4A):2599-601. PubMed ID: 10470201
[TBL] [Abstract][Full Text] [Related]
4. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
5. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.
Oremek GM; Sapoutzis N; Kramer W; Bickeböller R; Jonas D
Anticancer Res; 2000; 20(6D):5095-8. PubMed ID: 11326675
[TBL] [Abstract][Full Text] [Related]
6. The pyruvate kinase isoenzyme M2 (Tu M2-PK) as a tumour marker for renal cell carcinoma.
Weinberger R; Appel B; Stein A; Metz Y; Neheman A; Barak M
Eur J Cancer Care (Engl); 2007 Jul; 16(4):333-7. PubMed ID: 17587357
[TBL] [Abstract][Full Text] [Related]
7. Pyruvate kinase type tumor M2 in urological malignancies.
Hegele A; Varga Z; Kosche B; Stief T; Heidenreich A; Hofmann R
Urol Int; 2003; 70(1):55-8. PubMed ID: 12566817
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
Kaura B; Bagga R; Patel FD
J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
[TBL] [Abstract][Full Text] [Related]
9. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma.
Roigas J; Deger S; Schroeder J; Wille A; Turk I; Brux B; Jung K; Schnorr D; Loening SA
Urol Res; 2003 Dec; 31(6):358-62. PubMed ID: 14513300
[TBL] [Abstract][Full Text] [Related]
10. Determination of pyruvate kinase type tumor M2 in human renal cell carcinoma: a suitable tumor marker?
Varga Z; Hegele A; Stief T; Heidenreich A; Hofmann R
Urol Res; 2002 May; 30(2):122-5. PubMed ID: 12086017
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors.
Staib P; Hoffmann M; Schinköthe T
Clin Chem Lab Med; 2006; 44(1):28-31. PubMed ID: 16375581
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer.
Landt S; Jeschke S; Koeninger A; Thomas A; Heusner T; Korlach S; Ulm K; Schmidt P; Blohmer JU; Lichtenegger W; Sehouli J; Kuemmel S
Anticancer Res; 2010 Feb; 30(2):375-81. PubMed ID: 20332442
[TBL] [Abstract][Full Text] [Related]
13. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.
Ventrucci M; Cipolla A; Racchini C; Casadei R; Simoni P; Gullo L
Dig Dis Sci; 2004 Aug; 49(7-8):1149-55. PubMed ID: 15387337
[TBL] [Abstract][Full Text] [Related]
14. [Immunohistochemical demonstration of L- and M2-pyruvate kinase in primary renal cell carcinomas and their metastases].
Fischer G; Holzrichter S; Reinacher M; Heinrichs M; Dembowski J; Eigenbrodt E
Verh Dtsch Ges Pathol; 1989; 73():422-7. PubMed ID: 2482632
[TBL] [Abstract][Full Text] [Related]
15. [The significance of TU M2-PK tumor marker for lung cancer diagnostics].
Oremek G; Kukshaĭte R; Sapoutzis N; Ziolkowski P
Klin Med (Mosk); 2007; 85(7):56-8. PubMed ID: 17882813
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness of plasma tumor M2-pyruvate kinase in the diagnosis of gastrointestinal cancer].
Kim CW; Kim JI; Park SH; Han JY; Kim JK; Chung KW; Sun HS
Korean J Gastroenterol; 2003 Nov; 42(5):387-93. PubMed ID: 14646575
[TBL] [Abstract][Full Text] [Related]
17. Value of tumor M2-PK in thyroid carcinoma: a pilot study.
Bena-Boupda NF; Rezai SS; Klett R; Eigenbrodt E; Bauer R
Anticancer Res; 2003; 23(6D):5237-40. PubMed ID: 14981996
[TBL] [Abstract][Full Text] [Related]
18. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
Ervens J; Fuchs H; Niemann VT; Hoffmeister B
J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
[TBL] [Abstract][Full Text] [Related]
20. Tumor marker pyruvate kinase type tumor M2 in patients suffering from diabetic nephropathy.
Oremek GM; Rutner F; Sapoutzis N; Sauer-Eppel H
Anticancer Res; 2003; 23(2A):1155-8. PubMed ID: 12820364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]